1. Home
  2. VNT vs BLCO Comparison

VNT vs BLCO Comparison

Compare VNT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vontier Corporation

VNT

Vontier Corporation

HOLD

Current Price

$37.71

Market Cap

5.4B

Sector

Industrials

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$17.04

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VNT
BLCO
Founded
2019
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Ophthalmic Goods
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.0B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
VNT
BLCO
Price
$37.71
$17.04
Analyst Decision
Buy
Hold
Analyst Count
9
14
Target Price
$46.11
$17.31
AVG Volume (30 Days)
1.2M
341.8K
Earning Date
02-12-2026
02-18-2026
Dividend Yield
0.26%
N/A
EPS Growth
4.02
N/A
EPS
2.73
N/A
Revenue
$3,043,900,000.00
$4,976,000,000.00
Revenue This Year
$2.79
$8.06
Revenue Next Year
$3.10
$5.79
P/E Ratio
$13.90
N/A
Revenue Growth
1.76
6.23
52 Week Low
$27.22
$10.45
52 Week High
$43.88
$18.55

Technical Indicators

Market Signals
Indicator
VNT
BLCO
Relative Strength Index (RSI) 55.25 58.60
Support Level $37.58 $16.76
Resistance Level $38.27 $17.23
Average True Range (ATR) 0.58 0.32
MACD 0.16 -0.03
Stochastic Oscillator 76.14 63.68

Price Performance

Historical Comparison
VNT
BLCO

About VNT Vontier Corporation

Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: